A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)

NCT01702857 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

FED

Sponsor class

Conditions

Dengue Fever

Interventions

BIOLOGICAL: Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant
BIOLOGICAL: Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant
OTHER: Phosphate buffered saline
BIOLOGICAL: 1 µg TDENV-PIV with Alum adjuvant
BIOLOGICAL: 1 µg TDENV-PIV with AS01E adjuvant

Sponsor

U.S. Army Medical Research and Development Command

Collaborators

[object Object]
[object Object]